Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer

Not Recruiting

Trial ID: NCT00350142


This study will assess the efficacy of treating locally advanced pancreatic cancer using Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine

Official Title

Phase II Study to Evaluate the Efficacy of Trilogy Stereotactic Radiosurgery for Pancreatic Cancer

Stanford Investigator(s)

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine


Inclusion Criteria:- Pancreatic tumors not to exceed 10 cm in greatest axial dimension

   - Histologically confirmed malignancies of the pancreas

   - Unresectable by CT criteria or exploratory laparotomy or laparoscopy

   - Patients with metastatic disease may be treated if they are symptomatic from the
   primary tumor

   - Performance status of 0, 1, or 2

   - No chemotherapy two weeks prior or two weeks following radiosurgery

Exclusion Criteria:

   - patients who have had prior radiotherapy to upper abdomen

   - patients receiving any prior pancreatic cancer therapy

   - children, pregnant, and breastfeeding women, and lab personnel are excluded

   - uncontrolled intercurrent illnesses

   - any concurrent malignancy


other: 4D pancreatic protocol CT scan

radiation: FDG PET scan

radiation: Stereotactic Body Radiotherapy

drug: Gemcitabine

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jeff Kim

New Trial Alerts